Breast Clinical Trials

The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive HER2-Negative, Oncotype Recurrence Score < 18 Breast Cancer (DEBRA) De-Escalation of Breast Radiation

Protocol NRG-BR009, A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET) (NCT05879926)

NRG-BR008, "A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer” (HERO)

 A Phase II Trial of Sacituzumab Govitecan for Patients with HER2-Negative Breast Cancer and Brain Metastases

PHASE 2 TRIAL OF FULVESTRANT AND BINIMETINIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER WITH A FRAMESHIFT OR NONSENSE MUTATION OR GENOMIC DELETION IN NF1

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (Aspen)

WF-2202, Optimizing Psychosocial Intervention for Breast Cancer-related Sexual Morbidity: The Sexual Health and Intimacy Education (SHINE) Trial

EAQ221CD: Improving Medication Adherence in Metastatic Breast Cancer using a CONnected CUstomized Treatment Platform (CONCURxP)

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

NRG CC011-Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial